Stock Taper Revenue: $1.49 billion, a 3.3% increase year-over-year.
Adjusted EBITDA: $285 million, down 11.8% year-over-year, with an adjusted EBITDA margin of 19.1%.
Net Loss: $28.3 million compared to net income of $80.8 million in the prior year, primarily due to IPO-related expenses and lower revenue estimates from the No Surprises Act.
Operating Expenses: Increased 19.4% to $1.43 billion, driven by higher employee wages and inflationary costs.
Net Leverage: 3.5x, improved from 4.3x year-over-year.
Cash Position: $420 million in cash and cash equivalents, with a borrowing capacity of $696 million.
GMR completed nearly 1.4 million patient encounters in Q2, including over 1.3 million ground medical services.
Continued growth in same-market revenue and expansion into new markets, with $21.3 million from new market starts.
Successful implementation of the 911 nurse navigation program, which saw a 50% increase in call navigations year-over-year.
Introduction of innovative solutions like Transport.net and Concierge to improve operational efficiency and patient care.
GMR is positioned as a leader in EMS, covering over 60% of the U.S. population and maintaining contracts with FEMA.
Full-year revenue guidance remains between $5.89 billion and $6.18 billion, with adjusted EBITDA expected between $1.135 billion and $1.195 billion.
Anticipated continued momentum in transport rates and volumes, despite challenges from the expiration of ACA exchange subsidies and ongoing inflationary pressures.
Adjusted EBITDA Decline: The decrease in adjusted EBITDA was attributed to a lack of favorable prior-year revenue adjustments and a significant drop in IDR-related revenue.
Increased Operating Costs: Rising employee wages, stock compensation, and inflationary pressures on fuel and maintenance costs are impacting margins.
Payer Mix Shift: A shift from commercial insurance to self-pay due to the expiration of ACA subsidies is expected to impact revenue.
Regulatory Risks: Potential changes to the IDR process could affect future revenue from claims.
The year-over-year decline in IDR revenue was significant, with a $74 million difference compared to the previous year, indicating improved revenue estimation accuracy.
The impact of the ACA subsidy expiration is expected to continue, with guidance factoring in a $15-$16 million quarterly headwind.
GMR's in-network contracts stand at approximately 69%, with ongoing efforts to increase this percentage for better cash flow and reduced denials.
The company is exploring M&A opportunities but remains cautious due to current market conditions and prioritizes deleveraging. Overall, GMR Solutions demonstrated solid operational performance in Q2 2026, but faces challenges related to rising costs, regulatory changes, and shifts in payer dynamics. The company remains optimistic about its growth strategy and operational efficiencies moving forward.
SOURCE: Q2 2026 EARNINGS CALL TRANSCRIPT